Vanguard Group’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-48,300
| Closed | -$17.9K | – | 4601 |
|
|
2023
Q3 | $17.9K | Buy |
48,300
+23,400
| +94% | +$13.4K | ﹤0.01% | 4505 |
|
|
2023
Q2 | $29.1K | Hold |
24,900
| – | – | ﹤0.01% | 4501 |
|
|
2023
Q1 | $42.3K | Buy |
+24,900
| New | +$63.3K | ﹤0.01% | 4488 |
|
|
2022
Q4 | – | Sell |
-1,458
| Closed | -$14K | – | 4634 |
|
|
2022
Q3 | $14K | Sell |
1,458
-28
| -2% | -$651 | ﹤0.01% | 4595 |
|
|
2022
Q2 | $50K | Sell |
1,486
-1,675
| -53% | -$78.3K | ﹤0.01% | 4587 |
|
|
2022
Q1 | $224K | Buy |
3,161
+551
| +21% | +$102K | ﹤0.01% | 4520 |
|
|
2021
Q4 | $800K | Sell |
2,610
-64
| -2% | -$40.1K | ﹤0.01% | 4323 |
|
|
2021
Q3 | $2.11M | Buy |
2,674
+9
| +0.3% | +$7.83K | ﹤0.01% | 4043 |
|
|
2021
Q2 | $2.84M | Sell |
2,665
-115
| -4% | -$151K | ﹤0.01% | 3858 |
|
|
2021
Q1 | $5.02M | Buy |
2,780
+2,426
| +685% | +$4.85M | ﹤0.01% | 3532 |
|
|
2020
Q4 | $500K | Buy |
354
+81
| +30% | +$166K | ﹤0.01% | 3949 |
|
|
2020
Q3 | $1.06M | Buy |
273
+3
| +1% | +$13.6K | ﹤0.01% | 3647 |
|
|
2020
Q2 | $1.57M | Sell |
270
-27
| -9% | -$130K | ﹤0.01% | 3504 |
|
|
2020
Q1 | $1.03M | Buy |
297
+26
| +10% | +$246K | ﹤0.01% | 3478 |
|
|
2019
Q4 | $2.62M | Buy |
+271
| New | +$2.31M | ﹤0.01% | 3371 |
|
Vanguard Group's BXRX Position: Q4 2023 in Review
Vanguard Group sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 48,300 shares — an estimated $17.9K sold.
Vanguard Group first reported a position in BXRX in Q4 2019 and held it in 15 quarters. The position peaked at $5.02M in Q1 2021. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.
- Vanguard Group reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Vanguard Group sold 48,300 Baudax Bio, Inc. Common Stock shares in Q4 2023, an estimated $17.9K.
- Vanguard Group first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 15 quarters.
- Vanguard Group's Baudax Bio, Inc. Common Stock position peaked at $5.02M in Q1 2021.
- 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.
Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.